CJ Bioscience, Inc. (KOSDAQ: 311690)
South Korea
· Delayed Price · Currency is KRW 11,490
-220 (-1.88%)
Sep 11, 2024, 9:00 AM KST
CJ Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -21,166 | -22,913 | -34,913 | -19,272 | -8,763 | -4,346 | Upgrade
|
| Depreciation & Amortization | 4,754 | 5,146 | 3,900 | 1,562 | 1,051 | 730.98 | Upgrade
|
| Loss (Gain) From Sale of Assets | -8,719 | -8,718 | 366.99 | -10.43 | 89.96 | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 170.67 | - | - | Upgrade
|
| Stock-Based Compensation | -0 | 141.5 | 543.83 | 555.76 | 133.93 | 676.97 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | - | 105.27 | - | - | Upgrade
|
| Other Operating Activities | 1,575 | 1,880 | 3,375 | 9,460 | 667.78 | 262.56 | Upgrade
|
| Change in Accounts Receivable | 16.42 | 142.18 | -70.3 | -191.24 | -3.25 | 184.05 | Upgrade
|
| Change in Inventory | -95.19 | -81.66 | 69.66 | -231.19 | -265.64 | 47.14 | Upgrade
|
| Change in Accounts Payable | -106.84 | -213.84 | 48.91 | -421.5 | 420.07 | 21.83 | Upgrade
|
| Change in Unearned Revenue | 86.46 | 119.84 | 211.49 | 53.71 | 31.82 | -67.66 | Upgrade
|
| Change in Other Net Operating Assets | -1,494 | -401.61 | 5,505 | -218.1 | -1,342 | -16.3 | Upgrade
|
| Operating Cash Flow | -25,149 | -24,899 | -20,963 | -8,437 | -7,978 | -2,506 | Upgrade
|
| Capital Expenditures | -1,069 | -4,924 | -4,145 | -952.65 | -12,018 | -427.22 | Upgrade
|
| Sale of Property, Plant & Equipment | 33,116 | 33,116 | 85.09 | 10.45 | - | - | Upgrade
|
| Cash Acquisitions | - | - | -6,239 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1,696 | -11,493 | -725.5 | -26.1 | -2.32 | -26.13 | Upgrade
|
| Investment in Securities | 0.21 | 0.21 | 18,018 | 7,158 | -513.34 | -25,712 | Upgrade
|
| Other Investing Activities | - | -0 | 171.58 | 262.42 | -0 | - | Upgrade
|
| Investing Cash Flow | 30,351 | 16,699 | 7,165 | 6,453 | -26,506 | -26,165 | Upgrade
|
| Short-Term Debt Issued | - | 1,305 | 2,636 | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 41,996 | - | Upgrade
|
| Total Debt Issued | 1,597 | 1,305 | 2,636 | - | 41,996 | - | Upgrade
|
| Long-Term Debt Repaid | - | -23,077 | -1,414 | -22,768 | -476.63 | -345.26 | Upgrade
|
| Net Debt Issued (Repaid) | -21,516 | -21,772 | 1,222 | -22,768 | 41,519 | -345.26 | Upgrade
|
| Issuance of Common Stock | 44,977 | 44,977 | 50 | 73,479 | 826.53 | 23,614 | Upgrade
|
| Other Financing Activities | -377.14 | -260.87 | -280.02 | -0 | 0 | 0 | Upgrade
|
| Financing Cash Flow | 23,083 | 22,944 | 992.18 | 50,711 | 42,345 | 23,269 | Upgrade
|
| Foreign Exchange Rate Adjustments | 20.73 | 26.74 | 69.69 | 78.4 | 40.87 | 8.77 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | - | - | 0 | Upgrade
|
| Net Cash Flow | 28,306 | 14,772 | -12,737 | 48,805 | 7,901 | -5,394 | Upgrade
|
| Free Cash Flow | -26,219 | -29,823 | -25,108 | -9,390 | -19,997 | -2,933 | Upgrade
|
| Free Cash Flow Margin | -535.19% | -534.93% | -616.19% | -215.22% | -376.48% | -61.33% | Upgrade
|
| Free Cash Flow Per Share | -3014.06 | -4210.07 | -4271.74 | -2208.24 | -5179.37 | -888.40 | Upgrade
|
| Cash Interest Paid | 257.14 | 190.87 | 30.02 | 361.12 | 249.03 | - | Upgrade
|
| Cash Income Tax Paid | 46.15 | 1.48 | 141.56 | 5.3 | 31.88 | -10.62 | Upgrade
|
| Levered Free Cash Flow | -18,234 | -32,209 | -17,249 | -6,708 | -17,565 | -1,702 | Upgrade
|
| Unlevered Free Cash Flow | -17,755 | -31,633 | -15,522 | -3,603 | -16,551 | -1,674 | Upgrade
|
| Change in Net Working Capital | 448.74 | 468.31 | -5,675 | -1,575 | 394.69 | -196.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.